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Prolonged shedding of viral RNA occurs in some individuals following SARS-CoV-2
infection. We perform comprehensive immunologic evaluation of one individual with
prolonged shedding. The case subject recovered from severe COVID-19 and tested
positive for SARS-CoV-2 viral RNA repeatedly as many as 87 days after the first positive
test, 97 days after symptom onset. The subject did not have any associated rise in anti-
Spike protein antibody titers or plasma neutralization activity, arguing against re-infection.
This index subject exhibited a profoundly diminished circulating CD8+ T cell population
and correspondingly low SARS-CoV-2-specific CD8+ T cell responses when compared
with a cohort of other recovering COVID-19 subjects. CD4+ T cell responses and
neutralizing antibody responses developed as expected in this individual. Our results
demonstrate that detectable viral RNA shedding in the upper airway can occur more than
3 months following infection in some individuals with COVID-19 and suggest that impaired
CD8+ T cells may play a role in prolonged viral RNA shedding.
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INTRODUCTION
Viral RNA shedding in the upper respiratory tract for more than 20 days following SARS-CoV-2
infection occurs in a small subset of patients. While most scientists and the United States Centers for
Disease Control and Prevention do not believe that viral RNA shed in the upper airway more than
20 days after the onset of COVID-19 symptoms remains infectious (1, 2), prolonged viral RNA
shedding does correlate with severity of COVID-19 illness and is most frequently observed in
elderly individuals and those admitted to the ICU (3, 4).
The presence of detectable viral RNAmay suggest ongoing, yet very low levels, of continued viral
replication following the resolution of symptoms when patients are no longer infectious.
Alternatively, delayed physiologic clearance of non-infectious viral products may be occurring in
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these individuals who continue to test positive. A recent report
demonstrates that at least a small subset of patients with a history
of stem-cell transplant, chimeric antigen receptor T cell therapy
or lymphoma with persistent viral shedding have virus that can
be recovered in cell culture up to 61 days after the onset of
symptoms (5). Understanding why some individuals have
delayed clearance of infectious virus and others have delayed
clearance of viral RNA may be important for determining




Subjects were recruited into two prospective observational
clinical studies. Recruitment into the studies required testing for
COVID-19 and subjects included in this report all tested positive
for SARS-CoV-2 viral RNA by an FDA-approved clinical PCR
assay. Both studies were approved by theWashingtonUniversity in
Saint Louis Institutional Review Board (Approval #’s 2020 03 085
and 2020 03 186). We collected and documented verbal consent
from each enrolled subject in order to conserve personal protective
equipment for direct patient care providers and limit exposure
risks for research coordinators and study administrative staff
related to the collection and maintenance of potentially
contaminated written informed consent documents. All subjects
enrolled in the study received a written copy of the consent
document to keep and subjects enrolled by a legally authorized
representative due to respiratory failure necessitating intubation
and mechanical ventilation were provided a written copy of the
consent document and verbally assented to continued participation
in the study following recovery from their illness. The studies
comply with the ethical standards of the Helsinki Declaration.
Blood was drawn at the indicated time-points into EDTA-
anticoagulated collection tubes and prepared into plasma and
peripheral blood mononuclear cells (PBMC) by Ficoll density
gradient centrifugation. Plasma was frozen and stored at -80°C.
PBMC were washed, counted, resuspended in 90% fetal bovine
serum with 10% DMSO and stored in liquid nitrogen.
Flow Cytometry
Thawed PBMC from subject # WU 350-013 were analyzed by
surface flow cytometry as previously described (6). Antibodies in
the surface flow-cytometry staining panel included: CD45 Alexa
Fluor 532 (clone HI30, Invitrogen), CD3 Alexa Fluor 700 (clone
UCHT1, BioLegend), CD4 Spark 685 (clone SK3, BioLegend),
CD8 BV421 (clone RPA-T8, BioLegend) and CD19 BV750
(clone HIB19, BioLegend). The panel also included Zombie
NIR viability stain (BioLegend). All antibodies were used at
pre-titrated optimal staining concentrations.
Plasma Viral Load Measurement
Plasma viral load measurement was performed as previously
described (7). Briefly, viral RNA was extracted from 100 µL or
200 µL of plasma using the QIAamp Viral Mini Kit (Qiagen) and
used immediately in the Bio-Rad SARS-CoV-2 ddPCR kit (Bio-
Rad). CDC Nucleocapsid gene primers were used. Data were
analyzed using QuantaSoft 1.7 and QuantaSoft Analysis Pro 1.0
software. The reproducible limit of detection of the assay is 313
viral copies per mL of plasma (7).
Plasma Cytokine Quantification
Thirty-five soluble human cytokines, chemokines and growth
factors were quantified from frozen plasma using a magnetic
cytokine panel (ThermoFisher). The assay was performed
according to the manufacturer’s instructions in duplicate and
analyzed on a Luminex FLEXMAP 3D instrument.
Intracellular Cytokine Stain for Antigen-
Specific T Cell Responses
Intracellular cytokine staining to detect antigen-specific CD4+
and CD8+ T cells was performed with pools of overlapping 17-
mer peptides from the nucleocapsid (N), membrane (M) and
Spike (S) proteins of SARS-CoV-2 (USA-WA1/2020 strain)
obtained from BEI Resources, NIAID, NIH. Lyophilized
peptides were re-suspended in 10% DMSO and water and then
pooled. Three pools were evaluated: 1) a combined N and M
pool, 90-peptides, 2) S1 [S1-668] pool, 94-peptides, 3) S2
[S659-1273] pool, 87-peptides. One million PBMC were co-
cultured with costimulatory antibodies directed against CD28
and CD49d along with the indicated pooled peptides at a final
concentration of 1 µg/mL of each individual peptide, or
alternatively with Phorbol 12-myristate 13-acetate (PMA)
(InvivoGen) and Ionomycin (InvivoGen) as a positive control
or a DMSO/peptide diluent-only negative control. Samples were
incubated for 1 hour before the addition of Brefeldin A and
monensin (both from BD Biosciences) and then incubated for an
additional 5 h. Surface staining was performed followed by
fixation in 1% paraformaldehyde, permeablization with a
washing buffer supplemented with 0.1% w/v saponin (Sigma)
and intracellular staining using fluorescently labeled antibodies
directed against cytokine antigens. We used the following
antibodies: CD45 Alexa Fluor 532 (clone HI30, Invitrogen),
CD3 Alexa Fluor 700 (clone UCHT1, BioLegend), CD4 APC-
Cy7 (clone OKT4, BioLegend), CD8 BV421 (clone RPA-T8,
BioLegend), IFN-gamma FITC (clone B27, BD Biosciences),
TNF-alpha PerCP-Cy5.5 (clone Mab11, BD Biosciences) and
IL-2 APC (clone 5344.111, BD Biosciences). The panel also
included Zombie NIR viability stain (BioLegend). All antibodies
were used at pre-titrated optimal staining concentrations.
Samples were run on a Cytek Aurora spectral flow cytometer
using SpectroFlo software (version 2.1.0, Cytek) and unmixed
before final analysis using FlowJo software (version 10, BD
Biosciences). The mean number of collected live singlet
lymphocytes per sample was more than 140,000. Stimulation
index was calculated as the frequency of live, singlet CD3+CD4+
(CD4 T cells) positive for any combination of IL-2 and IFN-
gamma expression or live, singlet CD3+CD8+ (CD8 T cells)
positive for any combination of IFN-gamma, IL-2 or TNF-alpha
expression in the stimulated samples divided by the frequency of
cytokine positive events in the negative vehicle-only control
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sample. Figures were prepared in Prism version 8 (GraphPad
Software, Inc).
Spike Receptor Binding Domain ELISA
SARS-CoV-2 S-receptor binding domain (RBD, residues 331
−524) was cloned into pFM1.2. The plasmid was transiently
transfected into Expi293F cells using ExpiFectamine reagent
(Thermo) and cell supernatants were harvested 96h after
transfection. SARS-CoV-2 S-RBD was recovered using nickel
agarose beads (Goldbio). Ninety-six-well plates (NuncMaxiSorp;
Thermo Fisher Scientific) were coated with 0.1 µg/well
recombinant S-RBD in 1X PBS (Gibco) at 4°C overnight.
Plates were blocked for 1.5 h at room temperature with
blocking solution [1X PBS supplemented with 0.05% Tween-20
(Sigma) and 10% FBS (Corning)]. Plasma samples were diluted
1:30 with blocking solution, serially diluted 3-fold, and incubated
for 1 h at room temperature. Plates were washed three times
with T-PBS (1X PBS supplemented with 0.05% Tween-20),
and 100 µL anti-human IgM-, IgG- or IgA-horseradish
peroxidase conjugated antibody (goat polyclonal; Jackson
ImmunoResearch) was added to appropriate wells and
incubated for 1 h at room temperature. Plates were washed 3
times with T-PBS and 3 times with 1X PBS, and 100 µL
peroxidase substrate (SigmaFast o-phenylenediamine
dihydrochloride; Sigma) was added to all wells. The reaction
was stopped after 5 min using 100 µL 1M hydrochloric acid, and
absorbance at 490 nm was read using a microtiter plate reader
(BioTek). Areas under the curve were calculated using Prism
version 8 (GraphPad Software, Inc).
Pseudotype VSV Neutralization
Detection of plasma antibodies that can neutralize a pseudotyped
VSV virus expressing the SARS-CoV-2 S protein was performed
as previously described (8). Briefly, various dilutions of heat-
inactivated plasma were incubated with 104 PFU of VSV-SARS-
CoV-2-S△21 virus for 1 hour at 37°C. Antibody-virus complexes
were added to Vero E6 cells and incubated for 7.5 h at 37°C. Cells
were then fixed and stained with Hoechst 33342 nuclear stain
(Invitrogen). Images were acquired with the InCell 2000
Analyzer (GE Healthcare) automated microscope to visualize
nuclei and infected cells (eGFP-positive cells). Images were
analyzed in InCell Analyzer 1000 Workstation Software (GE




The index subject, WU 350-013, is an 80-85-year-old male with a
medical history of coronary artery disease, chronic kidney
disease stage 3, hypertension and hyperlipidemia who
developed symptoms of a viral respiratory illness 10 days prior
to hospital presentation. We enrolled WU 350-013 in the study
following return of a positive SARS-CoV-2 clinical PCR test one
day after the test was sent to the laboratory for processing. We
collected all study samples according to the timeline and protocol
established for the study. A timeline of the subject’s course of
illness, symptoms of COVID-19, sample collection time-points
and administered treatments during hospitalization is presented
in Figure 1.
WU 350-013 was discharged to a rehabilitation facility
following his initial 40-day admission for COVID-19 that
included 28 days of mechanical ventilation for acute
respiratory distress syndrome. WU 350-013 was then re-
admitted to hospital twice for reasons unrelated to COVID-19
25 days and then 37 days after his initial discharge from the
hospital (Figure 1). The subject was re-tested for COVID-19
during these two admissions on four separate occasions for
infection prevention reasons that required COVID-19 testing
for all patients admitted to specific areas of the hospital. The last
three of these four FDA-approved clinical PCR results returned
positive for SARS-CoV-2 viral RNA. The subject was ultimately
discharged back to rehabilitation and then to home following the
third hospital admission. The patient remained on isolation
precautions in his rehabilitation facility, therefore it is felt to be
FIGURE 1 | Timeline of study sample collection, administered treatments and clinical SARS-CoV-2 PCR test results for the case subject.
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highly unlikely that he was re-exposed to SARS-CoV-2 following
his first discharge from the hospital.
Comprehensive Immunologic Evaluation
We evaluated the subject’s immune response over the course of
his acute illness and recovery. We found a profoundly
diminished population of CD8+ T cells throughout his illness
and recovery as measured by percentage of CD8+ T cells in live
CD45+ PBMC, despite normal range values for CD4+ T cells and
CD19+ B cells (Figure 2A). In a separate experiment, we
measured the T cell population size in a cohort of PBMC
samples from recovering previously SARS-CoV-2-infected
subjects (N=14). Cohort clinical information is reported in
Supplementary Data Table 1. WU 350-013 had the smallest
CD8+ T cell population of the group and his CD4+ T cell
population size was at the mean for all recovering patient
samples (Figure 2A inset).
To better estimate the peak severity of the subject’s illness, we
measured SARS-CoV-2 viral replication and circulating plasma
cytokines as previously described (7, 9). Plasma viral load peaked
on the third day of study enrollment – the subject’s 15th day of
symptomatic illness (Figure 2B). Plasma viremia was detectable
in only a subset of critically ill mechanically ventilated COVID-
19 subjects, including WU 350-013 (inset, Figure 2B). Viral
replication in the airway, as measured by nasopharyngeal viral
load, remained high after the resolution of systemic viremia
(Figure 2C). The peak of systemic viral replication corresponded
to the peak of circulating plasma IL-8 and immediately preceded
the peak of several inflammatory plasma cytokines, including IL-
6 and MCP-1 (Figure 2D and Supplementary Figure 1).
Interestingly, plasma IP-10 concentrations decreased
throughout the study interval and plasma TNF-alpha did not
substantially increase from relatively low circulating values
throughout the course of severe COVID-19. TNF-alpha was
A B
DC
FIGURE 2 | Measurement of cell populations, SARS-CoV-2 viral replication and cytokines over time. (A) Frequency of circulating T cell and B cell populations in the
PBMC from WU 350-013 at various time-points post-study enrollment. Inset: in a separate experiment, the frequency of circulating T cell populations is reported in a
cohort of recovering COVID-19 subjects, including a sample from WU 350-013 (denoted in red) at day 78 post-study enrollment. (B) WU 350-013 plasma viral load
over time. Inset: Plasma viral load quantified in WU 350-013 (red) and a cohort of mechanically ventilated ICU subjects at day 0 and day 14 post-study enrollment.
Dashed line represents the limit of detection of the assay. (C) Cycle threshold or Ct values for clinical nasopharyngeal SARS-CoV-2 testing performed on WU 350-
013 throughout the course of the study. Lower Ct values represent a higher burden of viral replication. (D) Concentration of select cytokines in plasma from WU 350-
013 over time.
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elevated at the final day 78 sample collection time-point which
appeared to be unrelated to COVID-19 or any respiratory illness
and was due to an acute exacerbation of the subject’s heart failure
with hypotension that required dobutamine and norepinephrine
administration during the third hospitalization.
Finally, we measured the antigen-specific response in WU
350-013 over time. We assessed SARS-CoV-2 specific CD8+ and
CD4+ T cell responses to the Nucleocapsid (N), Membrane (M)
and Spike (S) proteins, the three principal targets of CD8+ and
CD4+ T cell responses in COVID-19-infected individuals (10).
We found no significant SARS-CoV-2 specific CD8+ T cell
responses in samples obtained from WU 350-013 prior to the
day 78 post-enrollment sample, when WU 350-013 responded
just above the median of all other recovering subjects to only the
S2 subunit of the spike protein. There were no detectable CD8+
T cell responses to the N, M or S1 antigens (Figure 3A). The
stimulation index we measured is normalized to the response
frequency found within all CD8+ T cells, and WU 350-013
had the lowest number of circulating CD8+ T cells in the
cohort, further diluting this single detected S2 response when
compared with the other subjects in the cohort. Analysis of
background-subtracted frequencies of responding CD8+ T cells
was consistent with our analysis of stimulation index
(Supplementary Figure 2). We observed low antigen-specific
CD8+ T cell responses in WU 350-013 despite robust day 78
post-enrollment SARS-CoV-2-specific CD4+ T cell responses in
this individual (Figure 3B). SARS-CoV-2-specific CD8+
response magnitudes were lower than SARS-CoV-2-specific
CD4+ T cell response magnitudes across the cohort of 15 tested
subjects (insets Figure 3), as others have previously noted
(10, 11). WU 350-013’s antigen-specific CD8+ T cell response
was below the median value for the N, M and S1 antigens,
above the median value for the S2 antigen and the CD4+ T cell
response was above the median value for each measured antigen
(insets Figure 3).
WU 350-013 developed early and robust S-RBD-specific IgG,
IgA and IgM antibodies prior to the study sample collected on
the 7th day following enrollment, 20 days after the start of
symptoms (Figure 3C). The appearance of these antibodies
corresponded with the appearance of virus neutralizing
antibodies in the subject’s plasma (Figure 3C). Of note, WU
350-013 developed high-titer neutralizing antibodies by study
day 7, six days before the administration of convalescent plasma.
Finally, there was no change in the steady rate of decline of
antibody responses at the day 78 sample time-point which was
taken 10 days after the first of three late-stage positive test results,
arguing against a second infection with SARS-CoV-2 prior to the
final study sample.
DISCUSSION
We describe a case of prolonged SARS-CoV-2 viral RNA
shedding lasting 87 days after the initial positive clinical PCR
test and 97 days after the onset of symptoms. This length of
viral RNA shedding is weeks longer than the majority of
prolonged viral shedding cases currently reported in the
literature (1–4), however, others have recently reported
shedding for similar or longer periods of time in a handful of
individuals (5, 12). One of these studies has shown that a small
number of individuals can shed viable virus that can be cultured
ex vivo (5). There are no indications in this subject’s immune
response that suggest he was re-infected with the virus.
Inflammatory cytokines at the latest study time-point did not
mirror changes seen during acute infection and antibody titers
continued a downward trajectory without suggestion of a
secondary antibody response late in the course of the
patient’s recovery while clinical SARS-CoV-2 PCR testing
remained positive. Furthermore, the clinical nasopharyngeal
A B C
FIGURE 3 | Case subject adaptive immune response over time. (A) WU 350-013 SARS-CoV-2-specific CD8+ T cell response to overlapping peptide pools from N,
M and S viral proteins as measured by intracellular cytokine staining (ICS) assay at various study time-points. Dotted line is at stimulation index of 1. Inset: CD8+ T
cell ICS response to peptide pools from the cohort of recovered COVID-19 subjects, including the day 78 post-study enrollment sample from WU 350-013 (red).
(B) WU 350-013 SARS-CoV-2-specific CD4+ T cell response to overlapping peptide pools from N, M and S viral proteins as measured by ICS at various study time-
points. Dotted line is at stimulation index of 1. Inset: CD4+ T cell ICS response to peptide pools from recovered COVID-19 subjects, including the day 78 post-study
enrollment sample from WU 350-013 (red). (C) Development of plasma spike protein receptor binding domain-binding antibodies (left axis, closed symbols) and
pseudotyped VSV (expressing SARS-CoV-2 spike protein) neutralizing antibodies in plasma (right axis, open symbols) over time. Light dotted line represents ELISA
area under the curve of SARS-CoV-2 negative control plasma; heavy dotted line represents plasma neutralization limit of detection.
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PCR samples from WU 350-013 maintained high Ct values
throughout the later course of the disease correlating with very
low viral load in the nasopharynx. Of note, we did not attempt
to culture virus from this individual to determine if they
harbored replicating virus, but the very high Ct values in the
nasopharyngeal samples late in the study suggest that if live
virus were present, the risk of transmission would be very low.
Therefore, the prolonged shedding interval in this individual
does seem most consistent with impaired clearance of viral
material rather than ongoing high levels of viral replication.
Interestingly, the studied subject exhibited relatively normal
appearing anti-SARS-CoV-2 antibody and CD4+ T cell
responses but demonstrated severely reduced CD8+ T cell
population size throughout his illness and correspondingly
low antigen-specific CD8+ T cell responses.
The role of antigen-specific CD8+ T cell responses in
COVID-19 has not yet been fully elucidated. We have
observed in this study and others have reported that the
overall magnitude of the antigen-specific CD8+ T cell response
to SARS-CoV-2 is low in individuals recovering from this
disease, nearly all of whom successfully clear the virus within
10 to 20 days (10). We and others have also reported upon the
depletion of T lymphocytes, specifically CD8+ T lymphocytes,
during acute SARS-CoV-2 infection, especially in individuals
with critical illness (9, 11, 13). Similar depletions occur in
individuals with acute influenza (6, 9) which may affect
antigen-specific CD8+ T cell responses in individuals with
symptomatic influenza illness (6). Diminished circulating
CD8+ T cell population size during acute illness may
ultimately impair the host’s ability to generate a large and/or
diverse antigen-specific CD8+ T cell response, as suggested by
this clinical case. Follow-up study in larger cohorts of patients
is needed.
Given the importance of CD8+ T cells in the clearance of
viral infections (14, 15), we believe that our observations of
such prolonged viral RNA shedding reflect this individual’s
uniquely poor CD8+ T cell response during the first three
months of his illness. We propose that vaccines which engender
SARS-CoV-2-specific CD8+ T cell responses may shorten the
interval between viral infection and clearance. Furthermore, the
observation that prolonged viral shedding occurs more
frequently in individuals with severe illness (4) suggests the
possibility that illness severity might also be reduced in
individuals with vaccine-enhanced SARS-CoV-2-specific
CD8+ T cell responses.
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